BCL2 like 10Genealiases: BCL-B · Boo · Diva · bcl2-L-10
Q-omics provides the consensus-scored BCL2L10 profile across patient tissues and cancer cell-line models. BCL2L10 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, BCL2L10 is differentially expressed in 10, with the highest sampling consensus in KIRP. Additionally, BCL2L10 RNA expression shows 11,826 significant gene co-expression associations, with the highest sampling consensus in PCPG. Together, these results highlight KIRP, and PCPG as cancer lineages where BCL2L10 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for BCL2L10 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes BCL2L10 survival associations across molecular data types. BCL2L10 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (2) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible BCL2L10 RNA expression–survival associations across cancer types. High BCL2L10 expression shows unfavorable associations in MESO, ESCA and SCLC, but favorable associations in KIRP, ACC and OV. The KIRP Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRP as the clearest survival context for BCL2L10 RNA expression.
This table summarizes BCL2L10 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10, while mass-spec protein shows differences in 1. The strongest signals are observed in KIRC for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for BCL2L10. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. BCL2L10 shows lower tumor expression in KIRP, KIRC, KICH and BRCA and higher tumor expression in LUSC and LUAD. The KIRP box plot shows higher BCL2L10 RNA expression in normal versus tumor tissue (log2 FC = −2.070, t-test p < 0.001).
This table shows molecular features associated with BCL2L10 in patient tissues and cancer cell lines. In patient samples, BCL2L10 shows the broadest associations at the RNA and protein expression levels, with PCPG recurring as the lineage with the largest associated feature set. In cancer cell lines, BCL2L10 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SKIN, while CRISPR and shRNA rows add functional-dependency signals in LIVER and CNS.
